Transcriptomics,Multiomics

Dataset Information

2

Gene expression profiling of neuroendocrine primary tumors: effect of Octreotide treatment


ABSTRACT: The management of neuroendocrine tumors (NETs) is very variable, depending on many specific aspects, such as the type of tumor, spread and patient general health. Several advances have been made with the newly developed somatostatin analogues to cure this type of malignancies. Somatostain analogues such as octreotide have been used in clinic to treat patients with neuroendocrine tumors (NETs). However, the molecular mechanism leading either to successful therapy or acquired resistance to the analogues is still to large extent unclear. Patients develop drugs resistance during a long term treatment. Therefore, to identify the pivotal regulatory genes involved in the development of drug resistance is an actual challenge. We studied five human neuroendocrine tumor cell lines, CNDT2.5, KRJ1, QGP-1, NCI H720 and NCI H727. We also investigated a long-term treated CNDT2.5 by using octreotide. We performed gene expression profiling in all the human neuroendocrine cell lines. Keywords: Gene Expression profiling, treatment comparison We investigated 5 human neuroendocrine cell lines, CNDT2.5 and KRJ1, established from ileum NETs, QGP1 by a pancreatic NET, NCI H720 and NCI H727 from bronchopulmonary NETs. CNDT2.5 cell were constantly treated with 1µM octreotide for 10 and 16 months. We isolated total RNA (Ambion, PARIS™ Kit) from 5 WT cell lines and CNDT2.5 treated with octreotide (Santostatin, Novartis). Total RNA was hybridized onto the Affymetrix Human Gene 1.0 ST Array by Affymetrix Uppsala Platform, UU. SE (Uppsala, Sweden). We first wanted to verify whether the different cell lines may become reliable models to study neuroendocrine signaling pathways. The main objective of this project aimed at understanding the mechanisms by which octrotide (Sandostatin, Novartis) alter cellular growth and differentiation of CNDT2.5 cells. We therefore focused on intermediate (10 months) and long stimulation (16 months) events triggered by sandostatin, which lead variation of CNDT.2.5 cells gene expression to identify potential pivotal genes involved in the development of drug resistance in neuroendocrine cells.

OTHER RELATED OMICS DATASETS IN: PRJNA132815

ORGANISM(S): Homo sapiens  

SUBMITTER: Su-Chen Li   Valeria Giandomenico  Ahmed Essaghir  Jean-Baptiste Demoulin 

PROVIDER: E-GEOD-24358 | ArrayExpress | 2012-12-12

SECONDARY ACCESSION(S): GSE24358PRJNA132815

REPOSITORIES: GEO, ArrayExpress

Dataset's files

Source:
Action DRS
E-GEOD-24358.idf.txt Idf
E-GEOD-24358.processed.1.zip Processed
E-GEOD-24358.raw.1.zip Raw
E-GEOD-24358.sdrf.txt Txt
Items per page:
1 - 4 of 4
altmetric image

Publications

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.

Li Su-Chen SC   Martijn Cécile C   Cui Tao T   Essaghir Ahmed A   Luque Raúl M RM   Demoulin Jean-Baptiste JB   Castaño Justo P JP   Öberg Kjell K   Giandomenico Valeria V  

PloS one 20121031 10


Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful disease control or symptom management, especially when SSTRs levels are low, are largely unknown. We provide novel insights into how octreotide controls NET cells. CNDT2.5 cells were treated from 1 day up to 16 months with octreotide and then were pro  ...[more]

Similar Datasets

| GSE24358 | GEO
2013-01-08 | E-MTAB-388 | BioStudies
2013-01-08 | E-MTAB-388 | ArrayExpress
2013-01-01 | S-EPMC3556255 | BioStudies
2012-01-01 | S-EPMC3481148 | BioStudies
2019-01-01 | S-EPMC6324631 | BioStudies
2017-01-01 | S-EPMC5726195 | BioStudies
2012-01-01 | S-EPMC3485222 | BioStudies
2012-01-01 | S-EPMC3380872 | BioStudies
2010-01-01 | S-EPMC4295034 | BioStudies